Federal Circuit hears arguments in Zarxio ‘patent dance’ row
The US Court of Appeals for the Federal Circuit has heard oral arguments in Amgen v Sandoz, a case that should determine whether it is mandatory for biosimilar applicants to engage in the so-called patent dance.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
22 July 2015 The US Court of Appeals for the Federal Circuit has ruled that biosimilar applicants can opt out of the so-called patent dance, paving the way for Sandoz to sell a biosimilar version of an Amgen drug.
22 July 2015 The US Court of Appeals for the Federal Circuit has ruled that biosimilar applicants can opt out of the so-called patent dance, paving the way for Sandoz to sell a biosimilar version of an Amgen drug.
22 July 2015 The US Court of Appeals for the Federal Circuit has ruled that biosimilar applicants can opt out of the so-called patent dance, paving the way for Sandoz to sell a biosimilar version of an Amgen drug.